Changes included simplifying tumor names, removing modifier terms such as “anaplastic”, distinguishing adult- and pediatric-type gliomas, and limiting the diagnosis of glioblastoma to IDH-wildtype disease. This evidence concerns the gene IDH1 and central nervous system cancer.